The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE President holds talks with US, Saudi Arabia leaders
Dubai's Parkin begins roll out of AI curb-side parking cameras
UAE, Kuwaiti Foreign Ministers discuss foiled infiltration operation by Iran's IRGC
UAE adds 16 individuals, 5 entities to terror list over Hezbollah links
UAE fully prepared to deal with hantavirus, any health threats
